Results 241 to 250 of about 1,734,521 (378)

Razing the scaffolding: the elimination of non-catalytic functions of kinases through targeted protein degradation. [PDF]

RSC Med Chem
Pogash S, Fletcher S.
europepmc   +1 more source

Effect of medium composition on protein degradation and DNA synthesis in rat embryo fibroblasts.

, 1977
Michael J. Warburton, Brian D. Poole
openalex   +1 more source

A Novel CHMP2B Splicing Variant in Atypical Presentation of Familial Frontotemporal Lobar Degeneration

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT C‐truncating variants in the charged multivesicular body protein 2B (CHMP2B) gene are a rare cause of frontotemporal lobar degeneration (FTLD), previously identified only in Denmark, Belgium, and China. We report a novel CHMP2B splice‐site variant (c.35‐1G>A) associated with familial FTLD in Spain. The cases were two monozygotic male twins who
Sara Rubio‐Guerra, Sara Bernal, David Almenta, Josefina Pérez‐Blanco, Valle Camacho, Isabel Sala, Mª Belén Sánchez‐Saudinós, Jesús García Castro, Judit Selma‐González, Miguel Ángel Santos‐Santos, Álvaro Carbayo, Janina Turon‐Sans, Ricard Rojas‐Garcia, Daniel Alcolea, Juan Fortea, Alberto Lleó, Oriol Dols‐Icardo, Ignacio Illán‐Gala   +17 more
wiley   +1 more source

Midnolin-proteasome pathway for protein degradation. [PDF]

MedComm (2020), 2023
Jin WL.
europepmc   +1 more source

Solid phase sequencing: A new support for the high sensitivity degradation of peptides and proteins

, 1975
John Bridgen
openalex   +1 more source

ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks between cycles) or a cycle followed by every‐other‐week (Q2W) dosing.
Ali A. Habib, Kristl G. Claeys, Vera Bril, Yessar Hussain, Kelly Gwathmey, Gregory Sahagian, Elena Cortés‐Vicente, Edward Brauer, Deborah Gelinas, Anne Sumbul, Rosa H. Jimenez, Daniela Hristova, Delphine Masschaele, Renato Mantegazza, Andreas Meisel, Shahram Attarian, On behalf of the ADAPT NXT Study Group   +16 more
wiley   +1 more source

PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation. [PDF]

Pharmaceutics
Syahputra EW, Lee H, Cho H, Park HJ, Park KS, Hwang D.   +5 more
europepmc   +1 more source

Protein degradation in the mouse blastocyst.

, 1979
Ralph L. Brinster, Susanne Brunner, Xavier Joseph, Irwin L. Levey   +3 more
openalex   +1 more source

Pathway Analyses of Inherited Neuropathies Identify Putative Common Mechanisms of Axon Degeneration

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Inherited neuropathies (IN) are associated with over 100 different genetic mutations presenting with a variety of phenotypes. This complexity suggests multiple pathways may converge onto a limited number of downstream pathways to effect axonal injury.
Christopher R. Cashman, Craig Blackstone, Reza Sadjadi   +2 more
wiley   +1 more source

Serine phosphorylation facilitates protein degradation by the human mitochondrial ClpXP protease. [PDF]

Proc Natl Acad Sci U S A
Feng Y, Goncalves MM, Jitkova Y, Keszei AFA, Yan Y, Sarathy C, St-Germain J, Kenney TMG, Tcheng M, Trudel V, Mancini RS, Upadhyay R, Hurren R, Gronda M, Schultz M, Soriano K, Lees K, Pomroy NC, Currie SQW, Privé GG, Reed MA, Yudin AK, Penn LZ, Arrowsmith CH, Raught B, Mazhab-Jafari MT, Vahidi S, Schimmer AD.   +27 more
europepmc   +1 more source